Lilly Secures License for Gene-Editing Tech to Develop Kidney Disease Drugs

• The deal includes an undisclosed upfront payment plus milestone-based payments tied to development, regulatory approvals, and sales, along with royalties on future product sales totaling up to $1.9 billion
• Ascidian's RNA exon-editing technology offers benefits similar to CRISPR gene editing but only changes RNA rather than permanently altering patient DNA
• Lilly has pursued multiple genetic medicine deals over the past year, including a $1.13 billion acquisition of Verve Therapeutics, as part of its strategic expansion in this space

Eli Lilly Secures $1.9B Gene-Editing Deal for Kidney Disease Therapies

Eli Lilly has entered a licensing agreement with Ascidian Therapeutics worth up to $1.9 billion to develop treatments for rare inherited kidney diseases using RNA exon-editing technology. Announced June 3, the deal grants Lilly exclusive rights to Ascidian's gene-editing platform for undisclosed kidney disease targets.

Deal Structure:

• Total value: up to $1.9 billion
• Includes undisclosed upfront payment plus milestone payments tied to development, regulatory approval, and sales
• Royalties on future product sales
• Ascidian leads early research and preclinical work; Lilly handles later development, manufacturing, and commercialization

Technology Advantages:

Ascidian's RNA exon-editing technology corrects faulty genes without permanently altering patient DNA, differentiating it from traditional CRISPR DNA-editing methods. According to Ascidian's Chief Business Officer Daniel Rosan, this approach provides CRISPR-like benefits while avoiding permanent DNA modification.

Strategic Context:

This transaction represents Lilly's continued expansion into genetic medicine, following multiple deals over the past year including the $1.13 billion acquisition of Verve Therapeutics and partnerships with AI-focused biotech firms and German companies. Ascidian previously licensed its technology to Roche in 2024 for neurological disease applications.

Market Implications:

The deal underscores growing pharmaceutical investment in gene-editing technologies and rare disease treatments. Lilly's aggressive pursuit of genetic medicine capabilities positions the company to address significant unmet needs in inherited kidney diseases while diversifying its therapeutic portfolio beyond its core diabetes and obesity franchises.